outperform price
thesi updat come analyst day main
question becam execut could deliv
promis given swirl macro uncertainti
answer defiant ye segment deliv
upsid ep came fy even adjust
capit gain standpoint seem
reason junctur although still need clariti
respect drug price return howev dd ep
growth still seem like stretch albeit compani
make progress number innov new program
technolog thank current valuat like reflect
market skeptic frankli like question whether
grow would say impli neg perp
growth forecast move higher across board howev
pt goe imput
opioid risk valuat methodolog frankli dont
see much risk intellectu standpoint
didnt creat demand rx came licens
physician may matter state citi need
fund deep pocket entiti combat crisi
expect vigor defend end
thought prudent account risk given
market clear belief even less respons
penal all-in surpris today reaction
given qualiti beat expect follow-thru
market volatil may actual point posit
cheap favor defens name
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
retail store convers health hub
hub end
expand metro area
strong result hub
strong consum feedback net promot score outpac
improv extra care program increas offer custom
custom look increas valu free deliveri access discount pilot market
well w/increas visit frequenc
juli healthi kid florida
strong exist relationship florida medicaid popul
competit product strong star perform geograph expans
provid coverag access live potenti
part preliminari benchmark result strong qualifi region
specif portion low end middl market specif region
live select geographi intensifi medic management geographi
still overal guidanc rang
individu health
remaind exist footprint
bid balanc approach
broad portfolio remain zero premium
new differenti offer healthhub home benefit across portfolio leverag
pharmacist pharmaci panel
current state
medicaid mbr line expect
new contract kansa perform thought would
silver script opp convers
success convers prior acquisit given largest pdp reposit good opp
continu growth busi product posit pdp help aetna stand-
alon abl convert skew earli end rang due transact
medic cost trend line gener
spec pharmaci area
note ordinari seen past
need done medic cost manag
comfort within rang initi guidanc upper half
pharma servic cost manag program strong client satisfact gross new biz
begin ingeniorx first wave may ad million end go well
chronic kidney plan earli access access home care receiv fda approv hemodialysi
plan home access alreadi enrol first patient includ patient
launch align trump kidney plan
meaning progress comprehens oncolog solut improv qualiti care reduc
cost launch provid plan patient high-touch engag enhanc patient experi
provid aetna member
flow use capit
juli repaid balanc
repaid approxim debt
approxim loss brazilian divestitur
pleas integr deliveri initi guidanc formulari optim
next year remain largest benefit pbm year goal
strong perform overal script
higher rebat earn quarter
drive formulari complianc cover rebat exposur
improv formulari complianc
specialti continu perform well
fulli expect rebat exposur peak year esp
dont target store count continu evalu real estat portfolio
new store open focus pacif northwest underserv big metro area like new
store come renewal/year
impact current trade issu materi busi
new guidanc rel base level beyond
strong momentum execut busi
remain confid lsd growth
rais distinctli item annual run rate
valuat methodolog base mix discount cash flow analysi rel valuat multipl
potenti elev govern scrutini drug price transpar neg impact long-
potenti on-line competit amazon erod front end comp margin us
continu reimburs pressur us eu hit ultim lead total margin
laboratori corp america
articl articl
time dissemin august
analyst elizabeth anderson ross muken michael newshel primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
